Amgen Settles On Bevacizumab And Trastuzumab
Genentech Had Failed To Enjoin Sales Of Biosimilars In US
Executive Summary
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
You may also be interested in...
Amgen Plays Both Sides As It Builds Out Inflammation Biosimilars
Amgen has reiterated the strength and capabilities of its dual commercial model by suggesting it will replicate its strategy for oncology biosimilars for its burgeoning inflammation product portfolio.
Amgen Takes Almost 40% Of US Bevacizumab Market
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.
Updated: Multiple Biosimilars To Avastin Have Launched In EU
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: